Latest Articles
-
The Outlook For Merck’s Diabetes Drug Business
Diabetes drugs are important to Merck (NYSE:MRK) and constitute nearly 15% of its value, according to our estimates. Most of this value can be attributed to Januvia and Janumet, with the rest coming from the phase 3 pipeline. Our analysis indic...
-
Merck Earnings Preview: It Is Going To Be All About Keytruda
Merck (NYSE:MRK) will report its Q4 2016 earnings on Feb 2nd. We expect decent results considering the recent momentum in its cancer drug Keytruda. Additionally, the company has received FDA approval for Zepatier, which is a Hepatitis C drug tar...
-
The Year 2016 In Review: Merck Can Look Back And Smile
Merck (NYSE:MRK) has had a reasonably good year. The company saw a turn-around in its business on the back of its relatively new cancer drug, Keytruda. The anti-infectives division sustained itself, with key metabolism drugs Januvia and Janumet ...
-
Merck’s Q3 Earning Review: Keytruda, The Key To Merck’s Growth
Merck (NYSE: MRK) reported its Q3’16 earnings on October 26th. The company posted revenue growth of 6% (excluding currency effects) for the last quarter on year-over-year basis. Keytruda, is turning out to be a winner in oncology space and we exp...
-
What To Expect From Merck’s Q3 Earnings?
Merck (NYSE: MRK) is set to report its Q3’16 earnings on October 25th. The company reported 3% revenue growth on constant currency basis for the second quarter and we believe revenue growth for Q3 continued at this rate. on top of this, in Q2 thi...
-
Why We Believe Merck Could Grow In Future?
Key Takeaways from Merck’s Earnings 1% growth in revenue, 79% rise in EPS Sales for new drugs Keytruda and, Zepatier grew more than 100% Januvia showed 4%-5% growth in terms of TRx volumes Remicade fell by 80% due to strong competition and p...
-
Why Vallee S.A. Acquisition Could Boost Merck’s Animal Health Business’ Growth In South America?
Merck has acquired 93% stake in Brazilian animal health product company, Vallee S.A,. for an approximate payment of $400 million. Vallee S.A. has a portfolio of over 100 products which include parasiticides, anti-infectives and vaccines. The comp...
-
Key Trends To Watch Out For Merck This Year
Have more questions about Merck? See the links below. What’s Merck’s Revenue And Earnings Breakdown In Terms Of Therapeutic Areas? What Led To Nearly 15% Decline In Merck’s Revenues & EBITDA In The Last 5 Years? ...
-
Why We Are Bullish On Merck
Have more questions about Merck? See the links below. What’s Merck’s Revenue And Earnings Breakdown In Terms Of Therapeutic Areas? What Led To Nearly 15% Decline In Merck’s Revenues & EBITDA In The Last 5 Years? H...
-
How Much Revenue Can Merck’s Cancer Drug Keytruda Add In 2020?
Merck’s Cancer Drug Keytruda Can Add Nearly $6 Billion In Revenue In 2020 ~ $2 Bil From Advanced Melanoma Therapy ~ $4 Bil From Lung Cancer Treatment Have more questions about Merck? See the links below. What’s M...
-
Why Merck’s Cancer Drug Keytruda Can Be Key To Its Long Term Growth?
Keytruda’s Growth Can Help Merck By: Mitigating Sales Loss Due To Patent Expiration Tapping In Huge And Growing Oncology (And Immuno-Oncology) Market Have more questions about Merck? See the links below. What’s MerckR...
-
Considering The EU Launch Of Biosimilar For Remicade, Merck’s 2nd Largest Drug, Does The Company Face Meaningful EPS Decline In 2016?
Merck’s EPS Impact Due To Remicade Biosimilar Competition In 2016 Is Insignificant, < 2% Have more questions about Merck? See the links below. What’s Merck’s Revenue And Earnings Breakdown In Terms Of Therapeutic Area...
-
How Much Revenues Can Merck’s Phase 3 Pipeline Add By 2020?
Merck’s Phase 3 Pipeline Can Add ~ $5 Bil In 2020 Have more questions about Merck? See the links below. What’s Merck’s Revenue And Earnings Breakdown In Terms Of Therapeutic Areas? What Led To Nearly 15% Decli...
-
By What Percentage Can Merck’s Revenue Grow Over The Next 3 Years?
Merck’s Revenue May Grow By Just 2% In The Next 3 Years Have more questions about Merck? See the links below. What’s Merck’s Revenue And Earnings Breakdown In Terms Of Therapeutic Areas? What Led To Nearly 15% Decline...
-
What’s Merck’s Revenue And Earnings Breakdown In Terms Of Therapeutic Areas?
Have more questions about Merck? See the links below. What’s Merck’s Fundamental Value Based On Expected 2015 Results? What Led To Nearly 15% Decline In Merck’s Revenues & EBITDA In The Last 5 Years? How Has Merck’s Re...
